Sex and Intimacy — While on Targeted Therapy

Yes. Condom use during targeted therapy is not only about preventing pregnancy. Some targeted therapy drugs are present in semen and vaginal secretions, which means your partner can be exposed to the drug through bodily fluids. NCCN guidance recommends barrier protection throughout treatment and for a period after your last dose, which your oncologist can specify for your particular drug. This applies regardless of your partner's sex or age.

The same precaution applies: the drug can be present in bodily fluids, including semen and vaginal secretions. NCCN guidance on barrier protection during treatment is intended to cover all forms of sexual contact where fluid exchange is possible, not intercourse alone. Ask your oncologist whether your specific drug carries this precaution and for how long after your last dose it continues. When in doubt, use barrier protection.

Yes, and this is more common than many patients expect. Fatigue is one of the most frequent causes — if you are exhausted, desire naturally falls. Some drugs affect hormone levels, which can reduce libido. Mood changes, anxiety about the diagnosis, and changes in body image also play a role. Tell your team if this is troubling you. Some causes can be identified and addressed, and knowing the reason is often reassuring in itself.

Yes, though these side effects can affect comfort significantly. Tell your team what you are experiencing — there are management strategies for both, including topical treatments and adjusting timing around your better days. Rashes associated with EGFR-targeted drugs are not contagious. If a particular position or activity is uncomfortable, communicating with your partner and finding what is comfortable is practical and reasonable. Your team can also refer you to a supportive care specialist if needed.

Pregnancy must be avoided during treatment. Most targeted therapy drugs are known or suspected to cause serious harm to a developing baby, and that risk applies whether you are the one who could become pregnant or whether your partner could. Effective contraception is required throughout treatment and for a period after it ends. The length of that period depends on the specific drug — your oncologist will tell you. If having children matters to you in future, raise fertility preservation before starting treatment, not after.

The answer depends on the specific drug. Different targeted therapies remain active in the body for different lengths of time after the last dose, and guidance on how long contraception and barrier protection should continue varies accordingly. Your oncologist or pharmacist can give you the specific recommendation for your drug. Do not assume the precautions end the day treatment stops — for some drugs the recommendation continues for weeks or months.

Tell them the concern is understandable, and that the precautions exist to make intimacy safe — not to stop it. Consistent contraception and condom use protect your partner from drug exposure and prevent pregnancy. Beyond that, physical intimacy does not worsen cancer or interfere with treatment. If pain or discomfort is the worry — from side effects rather than from intimacy itself — that is worth discussing with your oncology team, who can advise on what is causing it and whether it can be managed.

Yes. Your team needs to know in order to give you the right contraception guidance for your specific drug and to flag interactions between treatment and anything you might use for sexual health. Sexual health is a legitimate part of cancer care, and ASCO guidance recommends it be addressed routinely during oncology visits. If your team has not raised it, you can. A team experienced in cancer care will not be surprised by the question, and the answer may be more useful than you expect.